Luo Hai, Cui Lingzhi, Shen Kexin, Li Ruiqi, Wang Zeming, Xie Zhongshi
Gastrointestinal Colorectal and Anal Surgery, China-Japan Union Hospital of Jilin University, Changchun, Jilin, People's Republic of China.
General Surgery, The Second Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, People's Republic of China.
Cancer Manag Res. 2021 Apr 20;13:3443-3454. doi: 10.2147/CMAR.S297596. eCollection 2021.
This study was designed to investigate the correlation between the expression of human epidermal growth factor receptor 2 (HER2), mismatch repair (MMR), and clinicopathological parameters and serum tumor markers in a total of 522 resection samples materials from colorectal cancer (CRC) patients. These data were also used to determine the links between HER2 and MMR expression and prognosis.
We conducted a retrospective analysis of the clinical data from 522 CRC patients. Immunohistochemistry (IHC) was used to detect HER2 overexpression and MMR deficiency (dMMR) in tumor specimens which were then correlated with various clinicopathological parameters. Prognostic value for HER2 and MMR expression was then evaluated using the data from 105 CRC patients.
HER2 overexpression was identified in 35.63% of the samples evaluated in this study, while the total dMMR rate was 12.64%. Expression of HER2 and several, MMR proteins (MLH1, MSH-2, MSH-6, and PMS-2) were then correlated with tumor location. HER2 overexpression is significantly associated with increased depth of tumor invasion, lymph node metastasis, distant metastases, pTNM staging, vascular invasion, nerve infiltration, and serum carcinoembryonic antigen (CEA) levels. HER2 overexpression and dMMR increased with advancing clinical stage. In addition, deficiencies in MLH1 and PMS2 correlated with HER2 overexpression. Finally, the prognostic evaluations revealed that HER2 overexpression was closely associated with poorer clinical outcomes.
HER2 overexpression is significantly correlated with multiple clinicopathological parameters resulting in a poorer prognosis. Moreover, the prognosis of patients with HER2 overexpression was worse, confirming its significance during disease assessment. In clinical practice, clinicians should pay close attention to the HER2 profile of patients as they may require more extensive clinical intervention. In addition, deficiencies in MLH1, MSH-2, MSH-6, or PMS-2 correlate with tumor location, and MLH1 and PMS2 expression is associated with lymph node metastasis and pTNM stage, suggesting that these may be additional markers in CRC risk assessments.
本研究旨在调查522例结直肠癌（CRC）患者手术切除样本中人类表皮生长因子受体2（HER2）表达、错配修复（MMR）与临床病理参数及血清肿瘤标志物之间的相关性。这些数据还用于确定HER2和MMR表达与预后之间的联系。
我们对522例CRC患者的临床资料进行了回顾性分析。采用免疫组织化学（IHC）检测肿瘤标本中HER2过表达和MMR缺陷（dMMR），并将其与各种临床病理参数相关联。然后利用105例CRC患者的数据评估HER2和MMR表达的预后价值。
本研究评估的样本中，35.63%存在HER2过表达，而总的dMMR率为12.64%。HER2和几种MMR蛋白（MLH1、MSH-2、MSH-6和PMS-2）的表达与肿瘤位置相关。HER2过表达与肿瘤浸润深度增加、淋巴结转移、远处转移、pTNM分期、血管侵犯、神经浸润以及血清癌胚抗原（CEA）水平显著相关。HER2过表达和dMMR随临床分期进展而增加。此外，MLH1和PMS2缺陷与HER2过表达相关。最后，预后评估显示HER2过表达与较差的临床结局密切相关。
HER2过表达与多种临床病理参数显著相关，导致预后较差。此外，HER2过表达患者的预后更差，证实了其在疾病评估中的重要性。在临床实践中，临床医生应密切关注患者的HER2情况，因为他们可能需要更广泛的临床干预。此外，MLH1、MSH-2、MSH-6或PMS-2缺陷与肿瘤位置相关，MLH1和PMS2表达与淋巴结转移和pTNM分期相关，提示这些可能是CRC风险评估中的额外标志物。
